Critical Diagnostics

About Critical Diagnostics

Critical Diagnostics, founded in 2004 by David Geliebter and Sven Jacobson, is a San Diego-based company focused on developing and marketing novel biomarkers for cardiovascular diseases. The company holds exclusive worldwide rights to intellectual property for ST2, a biomarker discovered at Brigham and Women's Hospital, which it has since expanded through several patents.

The firm's core product is the Presage® ST2 Assay, an in-vitro diagnostic test that measures the level of soluble ST2 in a patient's blood serum or plasma. This test functions as a tool for physicians to assess the prognosis and stratify risk for patients diagnosed with chronic heart failure, helping to identify individuals at higher risk of adverse events and mortality. The measurement of ST2 provides insight into adverse cardiac remodeling and fibrosis. The Presage® ST2 Assay is cleared by the FDA in the U.S. and has received the CE Mark in Europe.

The business operates by providing these diagnostic tools to the healthcare industry, serving clinicians who manage patients with cardiovascular diseases. Its product line utilizes an enzyme-linked immunosorbent assay (ELISA) format. In addition to the Presage ST2 Assay, the company also markets related products such as the ASPECT–LF ST2 test and the ASPECT READER. Critical Diagnostics has secured a total of $11.1M in funding over three rounds, including a significant Series A round of $8.5M in January 2018, with Carrot Capital being an institutional investor.